DrugCite
Search

CHORIONIC GONADOTROPIN

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Chorionic Gonadotropin Adverse Events Reported to the FDA Over Time

How are Chorionic Gonadotropin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Chorionic Gonadotropin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Chorionic Gonadotropin is flagged as the suspect drug causing the adverse event.

Most Common Chorionic Gonadotropin Adverse Events Reported to the FDA

What are the most common Chorionic Gonadotropin adverse events reported to the FDA?

Ovarian Hyperstimulation Syndrome
122 (8.03%)
Ectopic Pregnancy
47 (3.09%)
Drug Exposure During Pregnancy
42 (2.76%)
Ascites
37 (2.43%)
Caesarean Section
31 (2.04%)
Ovarian Torsion
30 (1.97%)
Pleural Effusion
29 (1.91%)
Abortion Spontaneous
22 (1.45%)
Pregnancy
22 (1.45%)
Drug Exposure Before Pregnancy
19 (1.25%)
Ovarian Enlargement
18 (1.18%)
Show More Show More
Abdominal Pain
17 (1.12%)
Dyspnoea
17 (1.12%)
Nausea
16 (1.05%)
Vomiting
15 (.99%)
Abdominal Distension
14 (.92%)
Anaemia
13 (.86%)
Twin Pregnancy
12 (.79%)
Abortion Induced
11 (.72%)
Ovarian Cyst
11 (.72%)
Genital Haemorrhage
9 (.59%)
Headache
9 (.59%)
Ovarian Necrosis
9 (.59%)
Intra-abdominal Haemorrhage
8 (.53%)
Loss Of Consciousness
8 (.53%)
Maternal Drugs Affecting Foetus
8 (.53%)
Multiple Pregnancy
8 (.53%)
Premature Baby
8 (.53%)
Pulmonary Embolism
8 (.53%)
White Blood Cell Count Increased
8 (.53%)
Cerebral Infarction
7 (.46%)
Dizziness
7 (.46%)
Drug Ineffective
7 (.46%)
Hyponatraemia
7 (.46%)
Abdominal Pain Lower
6 (.39%)
Alanine Aminotransferase Increased
6 (.39%)
Alopecia
6 (.39%)
Aspartate Aminotransferase Increase...
6 (.39%)
Haemoglobin Decreased
6 (.39%)
Haemorrhage
6 (.39%)
Heterotopic Pregnancy
6 (.39%)
Hypersensitivity
6 (.39%)
Pelvic Pain
6 (.39%)
Peritonitis
6 (.39%)
Tachycardia
6 (.39%)
Abortion Threatened
5 (.33%)
Cephalo-pelvic Disproportion
5 (.33%)
Diarrhoea
5 (.33%)
Disseminated Intravascular Coagulat...
5 (.33%)
Haematocrit Increased
5 (.33%)
Haemorrhagic Ascites
5 (.33%)
Intra-uterine Death
5 (.33%)
Jugular Vein Thrombosis
5 (.33%)
Ovarian Rupture
5 (.33%)
Pelvic Fluid Collection
5 (.33%)
Poor Quality Drug Administered
5 (.33%)
Premature Rupture Of Membranes
5 (.33%)
Pyrexia
5 (.33%)
Ruptured Ectopic Pregnancy
5 (.33%)
Vaginal Haemorrhage
5 (.33%)
Weight Increased
5 (.33%)
Acute Respiratory Failure
4 (.26%)
Asthenia
4 (.26%)
Blood Bilirubin Increased
4 (.26%)
Blood Pressure Systolic Inspiratory...
4 (.26%)
Breech Presentation
4 (.26%)
Cardiac Tamponade
4 (.26%)
Carotid Artery Thrombosis
4 (.26%)
Circulatory Collapse
4 (.26%)
Coma
4 (.26%)
Drug Effect Decreased
4 (.26%)
Haematocrit Decreased
4 (.26%)
Hypovolaemic Shock
4 (.26%)
Inflammation
4 (.26%)
Malaise
4 (.26%)
Myocardial Infarction
4 (.26%)
Neck Pain
4 (.26%)
Oedema Peripheral
4 (.26%)
Pain
4 (.26%)
Pancreatitis Acute
4 (.26%)
Polycystic Ovaries
4 (.26%)
Prader-willi Syndrome
4 (.26%)
Ureteric Obstruction
4 (.26%)
Apgar Score Low
3 (.2%)
Blood Sodium Decreased
3 (.2%)
Convulsion
3 (.2%)
Deep Vein Thrombosis
3 (.2%)
Dehydration
3 (.2%)
Depressed Level Of Consciousness
3 (.2%)
Depression
3 (.2%)
Disease Progression
3 (.2%)
Feeding Disorder Neonatal
3 (.2%)
Fibromyalgia
3 (.2%)
Flatulence
3 (.2%)
Hydronephrosis
3 (.2%)
Hydrothorax
3 (.2%)
Hydroureter
3 (.2%)
Hypoalbuminaemia
3 (.2%)
Hypotension
3 (.2%)
Hypoxia
3 (.2%)
Ill-defined Disorder
3 (.2%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Chorionic Gonadotropin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Chorionic Gonadotropin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Chorionic Gonadotropin

What are the most common Chorionic Gonadotropin adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Chorionic Gonadotropin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Chorionic Gonadotropin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Chorionic Gonadotropin According to Those Reporting Adverse Events

Why are people taking Chorionic Gonadotropin, according to those reporting adverse events to the FDA?

Ovulation Induction
75
In Vitro Fertilisation
53
Infertility
41
Product Used For Unknown Indication
33
Anovulatory Cycle
17
Assisted Fertilisation
16
Show More Show More
Weight Decreased
14
Weight Control
11
Ovarian Hyperstimulation Syndrome
10
Ovarian Disorder
7
Infertility Female
6
Artificial Insemination By Partner
5
Hypogonadism
5
Amenorrhoea
5
Obesity
5
Cryptorchism
4
Hypopituitarism
4
Infertility Male
4
Hypogonadism Male
4
Drug Use For Unknown Indication
4
Polycystic Ovaries
3
Transplant
3
Ill-defined Disorder
2
Ovarian Failure
2
Medical Diet
2
Oocyte Harvest
2
Hormone Therapy
2
Luteal Phase Deficiency
2
Overweight
2
Weight Loss Diet
2
Secondary Hypogonadism
1
Growth Retardation
1
Sedation
1
Drug Abuser
1
Dwarfism
1
Ovulation Disorder
1
Supplementation Therapy
1
Weight Abnormal
1
Headache
1
Oocyte Donation
1
Fallopian Tube Disorder
1
Hormone Replacement Therapy
1

Drug Labels

LabelLabelerEffective
Chorionic GonadotropinAPP Pharmaceuticals, LLC20-APR-11
PregnylOrganon Pharmaceuticals USA18-AUG-11
PregnylPhysicians Total Care, Inc.19-APR-12
PregnylOrganon USA Inc.21-AUG-12
NovarelFerring Pharmaceuticals Inc.07-SEP-12

Chorionic Gonadotropin Case Reports

What Chorionic Gonadotropin safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Chorionic Gonadotropin. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Chorionic Gonadotropin.